Verrica Pharmaceuticals Inc..
VRCA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing and commercializing novel treatments for skin diseases with significant unmet needs. Their primary focus is on developing and commercializing treatments for viral skin diseases, including molluscum contagiosum. ...Show More
Better Health for All
0
Verrica Pharmaceuticals' primary product, YCANTH®, is FDA-approved for treating molluscum contagiosum in patients aged 2 and older, and is also being developed for common warts.
1
This indicates that 100% of the company's core product portfolio delivers substantial health benefits. The company has no products associated with known negative health outcomes.
2
In 2024, research and development expenses were $11.8 million, while total operating expenses were $58.8 million.
3
This means R&D represents approximately 20.07% of operating expenses, which is not directly comparable to the rubric's 'share of R&D budget' or 'capital allocation' as a percentage of total revenue or total capital. The company received an $8 million milestone payment for initiating a global Phase 3 clinical trial for common warts.
4
The company conducts clinical trials, with YCANTH® having undergone Phase 3 trials involving approximately 500 patients, leading to FDA approval.
5
Fair Money & Economic Opportunity
0
No evidence available to assess Verrica Pharmaceuticals Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
-10
The CEO's 2023 compensation was $3,504,647, while the average U.S. worker earned $65,470 in 2023, resulting in a CEO to median pay ratio of approximately 53.53:1.
1
Employee reviews on Glassdoor indicate a culture and values rating of 1.7 out of 5 (34%) and a senior management rating of 1.7 out of 5 (34%).
2
Reviews describe "terrible leadership," "incompetent managers," "micromanagement," "heavy pressure," and a "negative corporate culture."
3
Fair Trade & Ethical Sourcing
0
No evidence available to assess Verrica Pharmaceuticals Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-60
Verrica Pharmaceuticals Inc. faces multiple shareholder lawsuits alleging that board members concealed obstacles for regulatory approval and made misleading statements regarding manufacturing deficiencies.
1
These allegations stem from the company receiving three Complete Response Letters (CRLs) from the FDA for its product VP-102 between July 2020 and May 2022, primarily due to issues at its contract manufacturing organization, Sterling Pharmaceuticals Services.
2
The FDA classified Sterling Pharmaceuticals Services as Voluntary Action Indicated (VAI).
3
Following an FDA denial of a new drug application on May 24, 2022, Verrica's share prices collapsed by approximately 64% on May 25, 2022.
4
The company has a formal whistleblower protection policy, but specific details regarding its implementation, such as hotline statistics or reporting mechanisms, are not publicly provided.
5
Kind to Animals
0
No evidence available to assess Verrica Pharmaceuticals Inc. on Kind to Animals.
No War, No Weapons
0
No evidence available to assess Verrica Pharmaceuticals Inc. on No War, No Weapons.
Planet-Friendly Business
0
Verrica Pharmaceuticals Inc. lacks publicly available data across all specific environmental performance metrics, including carbon emissions, renewable energy use, water consumption, waste diversion, and climate targets.
1
The company does not participate in any tracked reduction initiatives or disclosure networks.
2
Verrica has an ESG Risk Score of 42 (Severe) from finance.yahoo.com and 41.6 (Severe) from Sustainalytics, ranking it 821 out of 848 in its industry and indicating a significantly higher ESG risk than its peers.
3
Its DitchCarbon score of 23 is lower than 84% of the industry average, suggesting a lower level of reported climate action.
4
While the company's Code of Business Conduct and Ethics emphasizes adherence to environmental laws, no specific performance data or details on regulatory actions, violations, or compliance issues are provided.
5
Respect for Cultures & Communities
0
No specific, quantitative data points were found in the provided articles regarding Verrica Pharmaceuticals Inc.'s formal partnerships with community groups, revenue reinvested in local development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, grievance mechanisms, average complaint resolution time, FPIC participation, community governance inclusion, cultural preservation investment, local procurement share, indigenous supplier count, cultural site protection, social license to operate, charitable giving to cultural heritage organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion.
1
Safe & Smart Tech
0
No specific, concrete evidence was found in the provided articles to assess Verrica Pharmaceuticals Inc. against any of the Key Performance Indicators for the 'Safe & Smart Tech' ethical value. The articles primarily discuss financial performance, product development, regulatory interactions related to manufacturing deficiencies, and a class action lawsuit concerning these manufacturing issues. Information regarding data protection, cybersecurity investment, AI ethics, privacy certifications, or other related metrics was not available.
Zero Waste & Sustainable Products
-20
Verrica Pharmaceuticals provides instructions for the disposal of its YCANTH Applicator and Break Tool.
1
Damaged applicators, which are single-use, should be discarded in a sharps container and handled according to accepted medical practice and applicable law.
2
The YCANTH Break Tool can be placed in plastic recycling containers or general trash, and should be disposed of after 12 uses.
3
The company's Code of Business Conduct and Ethics generally states that employees must comply with all applicable environmental laws, noting that federal law imposes criminal liability for contaminating the environment with hazardous substances.
4